Serine--tRNA Ligase, Cytoplasmic (SARS1) Antibody
REQUEST MORE INFO
Catalogue No: abx005165
Price:
US$217.50
(Size: 20 µl)
Orders to United States ship from United States
Add to Cart
Buy It Now
GET A QUOTE
Documents
Datasheet SDS
Serine--tRNA Ligase, Cytoplasmic (SARS1) Antibody is a Rabbit Polyclonal antibody against SARS. This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown.
Research Articles on Serine--tRNA Ligase, Cytoplasmic (SARS1)
| Target | Serine--tRNA Ligase, Cytoplasmic (SARS1) |
| Clonality | Polyclonal |
| Reactivity | Human, Mouse, Rat |
| Tested Applications | ELISA, WB, IHC, IF/ICC |
| Host | Rabbit |
| Recommended dilutions | ELISA: 1 µg/ml, WB: 1/500 - 1/2000, IHC-P: 1/50 - 1/200, IF/ICC: 1/50 - 1/200. Not tested in IHC-F. Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Immunogen | Recombinant protein corresponding to SARS1. The exact sequence is proprietary. |
| Isotype | IgG |
| Form | Liquid |
| Purification | Purified by affinity chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Shelf Life | 12 months. |
| UniProt Primary AC | P49591 (UniProt, ExPASy) |
| UniProt Secondary AC | B2R6Y9, Q5T5C8, Q9NSE3 |
| UniProt Entry Name | SYSC_HUMAN |
| Gene Symbol | SARS1 |
| GeneID | 6301 |
| OMIM | 607529 |
| NCBI Accession | NP_006504.2 |
| KEGG | hsa:6301 |
| String | 9606.ENSP00000234677 |
| Molecular Weight | Calculated MW: 59 kDa Observed MW: 59 kDa |
| Buffer | PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol. |
| Concentration | > 0.2 mg/ml |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |



